SHANGHAI, April 16, 2024 /PRNewswire/ — Lufax Holding Ltd ("Lufax" or the "Company") (NYSE: LU and HKEX: 6623), a leading financial services enabler for small business owners in China, today announced that it plans to release its first quarter 2024 financial results after the market closes on Monday, April 22, 2024 U.S. Eastern Time.

The Company’s management will hold an earnings conference call at 9:00 P.M. U.S. Eastern Time on Monday, April 22, 2024 (9:00 A.M. Beijing Time on Tuesday, April 23, 2024) to discuss the financial results. For participants who wish to join the call, please complete online registration using the link provided below in advance of the conference call. Upon registering, each participant will receive a set of participant dial-in numbers, the event passcode, and a unique access PIN, which can be used to join the conference call.

Registration Link: https://dpregister.com/sreg/10188298/fc485dda60   

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.lufaxholding.com.

The replay will be accessible through April 29, 2024, by dialing the following numbers:

United States: 

1-877-344-7529

International: 

1-412-317-0088

Conference ID: 

8644039

About Lufax

Lufax is a leading financial services enabler for small business owners in China. The Company offers financing products designed principally to address the needs of small business owners. In doing so, the Company has established relationships with 85 financial institutions in China as funding partners, many of which have worked with the Company for over three years.

Investor Relations ContactLufax Holding LtdEmail: Investor_Relations@lu.com

ICR, LLCRobin YangTel: +1 (646) 308-0546Email: lufax.ir@icrinc.com

Source link

This content was prepared by our news partner, Cision PR Newswire. The opinions and the content published on this page are the author’s own and do not necessarily reflect the views of Siam News Network
You May Also Like

SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals

SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical…

Great Place To Work™ Greater China Celebrates the Best Workplaces™ in Hong Kong 2026

Inspiration — a core element of high‑trust leadership that nurtures culture, builds…

"Transfersome Gel" a New Solution for Hypertrophic Scars Chula Pharmacy's Latest Innovation

BANGKOK, Sept. 16, 2024 /PRNewswire/ — Lecturers at the Faculty of Pharmaceutical Sciences,…